


## Leveraging Small Business and Industry Assistance (SBIA) Resources

#### Renu Lal, PharmD, BCACP

Lieutenant Commander, US Public Health Service Team Lead | Division of Drug Information Deputy Director | SBIA Office of Communications CDER | US FDA


REdI Annual Conference – May 30, 2024



## **Learning Objectives**

- Locate the SBIA webpage and identify 3 resources SBIA offers that can help YOU
- Understand how to register for SBIA events and find recordings of past events

FD/



fda.gov/cdersbia

## **SBIA Mission**

- Provide industry stakeholders with immediate access to resources, education & training
- Allow for a more clearly informed and efficient developmental process
- Align with CDER's goal of approving safe and effective human drugs and biopharmaceuticals



## **SBIA** Audience





fda.gov/cdersbia

6

## Resources

- Direct Communication Services
- Webpages
- Training Resources
- News and Updates







• Phone: 301-796-6707 | 866-405-5367

## Email: <u>CDERSBIA@fda.hhs.gov</u> (Monday – Friday 8 AM – 4:30 PM ET)

fda.gov/cdersbia

8

## Training: Workshops and Conferences

CDER SMALL BUSINESS AND INDUSTRY ASSISTANCE (SBIA)

Use of Biomarkers for Diagnosing and Assessing Treatment Response in Noncirrhotic NASH Trials

VIA WEBCAST

SEPT 18-19 www.fda.gov/CDERSBIA

Small Business and Industry Assistance 2024 Regulatory Education for Industry Hybrid May 29-30 Small Business and Industry Assistance

Clinical Investigator Training Course (CITC)

> DECEMBER 6 – 7, 2023 Webcast

## **Training: Webinars**

#### Small Business and Industry Assistance Expanding Generic Drug Access



## **Training: SBIA Chronicles**



Short electronic newsletter and podcast, highlighting a specific regulatory issue in an easy-to-read format.

www.fda.gov/cdersbiachronicles

### CDER Small Business & Industry Assistance (SBIA)

A Comprehensive Resource for Information on Human Drug Development in Regulation

Subscribe to Email Updates	f Share	🗙 Post	in Linkedin	🔽 Email	🔒 Print
----------------------------	---------	--------	-------------	---------	---------

#### www.fda.gov/cdersbia

#### **Register for Upcoming Events**

Date	Time	Event	Location
April 10 - 11,	8:30 am -	Generic Drugs Forum (GDF) 2024: Regulatory Considerations to Enhance	Conference
2024	5:00 pm	Generic Drug Access	
April 25,	1:00 pm -	Facilitating Generic Drug Product Development through Product-Specific	Webinar
2024	4:00 pm	Guidances	
May 9, 2024	1:00 pm - 3:30 pm	Redesigned Pre-Submission Meetings in GDUFA III: Benefits for ANDA Submission and Approval	Webinar
May 16, 2024	1:00 pm - 2:30 pm	Statistical Considerations for Premarketing Risk Assessment	Webinar
May 29-30,	8:30 am -	Regulatory Education for Industry (REdI) Annual Conference 2024:	Conference
2024	4:30 pm	Innovation in Medical Product Development	



#### **REGULATORY REFERENCES, TRAINING, AND RESOURCES**



#### **Regulatory References**

Find information on drug development, applications, submissions, manufacturing & quality, safety, labeling and more



#### SBIA Learn Online Training Repository

Search for conferences, webinars, online courses, newsletters and podcasts




#### SBIA on LinkedIn

fda.gov/cdersbia

Stay connected and receive regulatory updates and event notifications

#### SBIA Learning Library on YouTube

Browse conference and webinar recordings on YouTube



# entries

Clear Filter

Export Excel


Show 10

#### **Regulatory References**

Find information on drug development, applications, submissions, manufacturing & quality, safety, labeling and more

14

FD/





#### SBIA Learn Online Training Repository

10

entries

Search for conferences, webinars, online courses, newsletters and podcasts

#### www.fda.gov/cdersbialearn

## **Poll: Improving CDER SBIA Learn**

Would <u>fda.gov/cdersbialearn</u> be more helpful if there was an option to:

- A. Filter by multiple tiers of topics (Broad to Specific)
- B. Filter by competency level (basic, intermediate, advanced)
- C. A & B

In-Person: *Show of Hands* Online Login 1: *Respond to Poll* 



#### A Deep Dive: FDA's Model-Integrated Evidence (MIE) Industry Meeting Pilot Program fo

U.S. Food and Drug Administration • 3.8K views • 3 months ago

Good Clinical Practice & Pharmacovigilance U.S. Food and Drug Administration • 16K views • Streamed 3 months ago



7:44:58

8:28:56

Good Clinical Practice & Pharmacovigilance Symposium



FDA-MHRA-HC 2024 Joint Symposium (Day 3)

FDA-MHRA-HC 2024 Joint Symposium (Day 2)

U.S. Food and Drug Administration • 7K views • Streamed 3 months ago

U.S. Food and Drug Administration • 7K views • Streamed 3 months ago



Good Clinical Practice & Pharmacovigilance Compliance Symposium Day One – AM U.S. Food and Drug Administration • 1.3K views • 2 months ago

SMALL BUSINESS and INDUSTRY ASSISTANCE

Good Clinical Practice & Pharmacovigilance Compliance Symposium Day One – PM U.S. Food and Drug Administration • 754 views • 2 months ago



Good Clinical Practice & Pharmacovigilance Compliance Symposium Day Two – AM

U.S. Food and Drug Administration • 1.2K views • 2 months ago




FDA → Playlists → CDER Small Business and Industry Assistance

17



#### CDER Small Business and Industry Assistance





#### SBIA on LinkedIn

Stay connected and receive regulatory updates and event notifications

## **News & Updates: Email Subscriptions**

FDA

FDA | CDER | Small Business and Industry Assistance

#### CONFERENCES

#### Regulatory Education for Industry (REdI) Annual Conference 2024

Innovation in Medical Product Development

Hybrid May 29 – 30 | 8:30 AM - 4:30 PM ET

No Fee Registration

C SHARE

#### DRUGS, DEVICES, AND BIOLOGICS

TRACKS WILL OFFER AN OPPORTUNITY FOR 1:1 QUESTIONS FOR ONSITE ATTENDEES

Learn directly from the FDA's regulatory experts in medical product centers: drugs, devices, and biologics. This course is designed to provide participants with a strong, basic foundation in the FDA's regulatory requirements, and also create awareness of current activities.



## FDA | CDER | Small Business and Industry Assistance

#### FDA establishes CDER Center for Clinical Trial Innovation (C3TI)

Today, FDA's Center for Drug Evaluation and Research (CDER) <u>announced</u> the launch of the CDER Center for Clinical Trial Innovation (C3TI). C3TI's mission is to promote CDER clinical trial innovation activities through enhanced communication and collaboration, both internally within CDER and externally.

"CDER's long-standing efforts to embed innovation in clinical trial design and conduct into our regulatory work have been crucial in bringing new therapies to areas of unmet medical need," said Patrizia Cavazzoni, M.D., director of CDER. "We are eager to build on this foundation by launching C3TI to further spur the adoption of clinical trial innovation across industry and within CDER."

For years, CDER has championed innovation, and our activities to foster and support innovation span drug development programs, therapeutic areas, and disciplines. These CDER efforts have led to improvements in the design and conduct of clinical trials that are intended to efficiently generate evidence on the safety and effectiveness of new therapies in ways that meet the growing demands of drug development.

Recently, we sought to understand the impact of these efforts by holding interviews, listening sessions, and a public workshop with both internal and external parties, and soliciting comments to a public <u>docket</u>. Based on these engagements, we recognize an opportunity to enhance the implementation of our innovative efforts and maximize the impact on drug development.

C3TI will be a central hub within CDER that supports innovative approaches to clinical trials that are designed to improve the efficiency of drug development. C3TI will facilitate the sharing of lessons learned across CDER's existing clinical trial innovation initiatives and will communicate and collaborate with external parties. C3TI will also manage a demonstration program that will expand opportunities for sponsors of innovative clinical trials to interact with CDER staff and for these trials to serve as case examples to spur further implementation. The three initial project areas under the C3TI Demonstration Program are 1) point-of-care or pragmatic trials; 2) Bayesian analyses; and 3) trials using selective safety data collection.

This new center within CDER will enable both internal and external parties to access information on clinical trial innovation efforts more easily, engage in collaborations, identify resources that can further support the use of innovative modalities, and identify development programs where a concerted approach to the use of clinical trial innovations would be impactful. The goals of these efforts are to assist those involved in clinical research in staying current with clinical trial innovations, improve the efficiency and effectiveness of clinical trials, help increase the participation of diverse populations in clinical trials, and, in turn, accelerate the development of safe and effective new drugs.

For more information about C3TI, including how to participate in a project in the C3TI Demonstration Program, explore the <u>C3TI webpage</u>. Visit the <u>CDER Conversation</u> with Dr. Kevin Bugin, deputy director for operations in CDER's Office of New Drugs and lead for C3TI to learn more about the impetus for establishing C3TI and the center's forward-facing goals and objectives.

## **Challenge Question #1**

FDA

In which of the SBIA resources can you find a database of searchable FDA webpages relating to drug development?

- A. Regulatory References
- B. SBIA Learn Online Training Repository
- C. Calendar of Upcoming Events
- D. SBIA Learning Library on YouTube

## **Challenge Question #2**



#### Which of the following statements is **NOT** true?

- A. You can stay connected with the latest regulatory information and offerings by subscribing to the SBIA listserv and following SBIA on LinkedIn
- B. Industry stakeholders may call or email SBIA directly
- C. SBIA's services are only available to companies with less than 500 employees
- D. SBIA offers free conferences, workshops and webinars on various regulatory topics

## Resources



SBIA webpage



SBIALearn







fda.gov/cdersbia

## **Summary and Call to Action**

- Email or call SBIA with your regulatory questions
  CDERSBIA@fda.hhs.gov | 866-405-5367 or 301-796-6707
- Bookmark <u>www.fda.gov/cdersbia</u> and <u>www.fda.gov/cdersbialearn</u>
- Browse the <u>CDER SBIA playlists</u> on FDA's YouTube channel
- Follow us on LinkedIn
- Subscribe to the <u>SBIA listserv</u>

## **CDER SBIA Learn Feedback**

Do you have suggestions for improvements on the usability <u>fda.gov/cdersbialearn</u>?

In-Person: *Please share them with me sometime today* 

Online Login 1: Enter your suggestions into the Poll question